Helix BioPharma, an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, has appointed Dr Theordore J. Witek to the board of directors.
Dr Witek brings more than three decades of clinical development, medical affairs and commercial experience to Helix's board. He currently holds the position of Senior Vice President, Corporate Partnerships and Chief Scientific Officer of Innoviva and is also a Professor and Senior Fellow at the Institute of Health Policy, Management & Evaluation at the Dalla Lana School of Public Health, University of Toronto.
Previously, Dr Witek served as President and CEO at Boehringer Ingelheim Canada. He holds a Doctor of Public Health degree from Columbia University, a Master of Public Health from Yale University, and a Master of Business Administration from Henley Management College.
'Ted's robust clinical, regulatory and medical affairs experience will add tremendous depth to Helix's board of directors,' said Dr Sven Rohmann, Chief Executive Officer of Helix.
